Myeloid-Derived Suppressor Cells (MDSCs) in Haematology
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: closed (10 July 2022) | Viewed by 33604
Special Issue Editor
2. Department of Hematology, University Hospital of Heraklion, 71500 Heraklion, Greece
Interests: neutropenia; bone marrow failure; clonal hematopoiesis; myeloid derived suppressor cells; umbilical cord blood
Special Issue Information
Dear Colleagues,
It is my honor to serve as the Guest Editor of the Special Issue “Myeloid-Derived Suppressor Cells (MDSCs) in Haematology” of the Journal of Clinical Medicine, and I would like to invite you to submit a relevant review and/or paper with new data from your research in the field. This issue will serve as a great opportunity to highlight the role of MDSCs in the pathophysiology of immune-mediated and malignant haematologic diseases and how research in the field may advance the clinical practice, particularly in the context of precision medicine.
MDSCs are immature myeloid cells with immunomodulating properties, mainly acting by suppressing T-cell responses. Most experimental and clinical studies concerning MDSCs have been focused on solid tumors, as these cells contribute to malignant cell expansion, local angiogenesis, and drug resistance. In recent years, however, the implication of MDSCs in the immune dysregulation associated with haematologic malignancies, immune-mediated cytopenias, and allogeneic haemopoietic stem cell transplantation has been documented; thus, the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest in haematology. There is already evidence that MDSCs display altered frequency and/or functionality and could be targeted in myelodysplastic syndromes, lymphomas, myeloproliferative neoplasms, leukemia, multiple myeloma, immune mediated cytopenias, and graft-versus-host disease. The better understanding of the quantitative/functional properties of MDSCs and the mechanisms of their crosstalk with other regulatory (e.g., T-cells, natural killer cells, mesenchymal stem cells) and malignant cells in haematologic diseases may facilitate the development of novel therapeutic strategies (i.e., blockage of development, differentiation, depletion, and deactivation of MDSCs) and the recognition of novel biomarkers for personalized treatment approaches. Thus, the issue aims to cover this broad spectrum.
I look forward to receiving your submissions.
Prof. Dr. Helen A. Papadaki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Myeloid-derived suppressor cells (MDSCs)
- Hematologic malignancies
- Immune-mediated cytopenias
- Graft-versus-host disease
- Therapeutic target
- Biomarker
- Precision medicine
- Immunosuppression
- Molecular pathways
- Bone marrow microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.